Welcome to our dedicated page for Kenvue news (Ticker: KVUE), a resource for investors and traders seeking the latest updates and insights on Kenvue stock.
Kenvue Inc. (NYSE: KVUE) is described as the world’s largest pure-play consumer health company by revenue, with a portfolio of science-backed brands such as Aveeno®, BAND-AID® Brand, Johnson’s®, Listerine®, Neutrogena®, Tylenol® and Zyrtec®. This news page aggregates company announcements, press releases and market-moving updates related to KVUE stock and Kenvue’s global consumer health operations.
Readers can find earnings news, including quarterly results where Kenvue reports net sales trends, organic sales performance, gross profit and operating income margins, and diluted and adjusted earnings per share. These releases often include management commentary on operating priorities, productivity initiatives, supply chain optimization efforts and updated outlooks for the fiscal year, along with explanations of non-GAAP measures such as Adjusted gross profit margin, Adjusted operating income margin, Adjusted net income, Adjusted EBITDA margin, Adjusted effective tax rate, Free cash flow and Organic sales.
The feed also covers strategic and corporate developments. In 2025, Kenvue announced a comprehensive review of strategic alternatives, leadership changes including a CEO transition, and a definitive agreement under which Kimberly-Clark Corporation will acquire all outstanding shares of Kenvue common stock in a cash and stock transaction, as detailed in joint press releases and a Form 8-K. Updates on this planned acquisition, board decisions and related shareholder communications are key topics for investors following KVUE news.
Additional items include dividend declarations by Kenvue’s Board of Directors, highlighting the company’s approach to returning capital to shareholders, and partnership and innovation news, such as the collaboration with Albert Invent to apply AI to Kenvue’s research and development processes. Together, these categories give investors, analysts and consumers a consolidated view of how Kenvue manages its brand portfolio, financial performance and strategic direction. Bookmark this page to quickly access the latest official Kenvue updates relevant to KVUE stock.
Kenvue, the world's largest pure-play consumer health company by revenue, has released its first Healthy Lives Mission Report. The report highlights significant progress in Environmental, Social, and Governance (ESG) goals since becoming an independent company. Key achievements include a 26% reduction in Scope 1 and 2 GHG emissions since 2020, increased use of renewable electricity to 65%, and 71% of their packaging being recyclable or refillable. The company also reports gender parity in its global workforce and a commitment to diversity, with 36% of U.S. employees identifying as racial or ethnic minorities. Kenvue continues to develop inclusive products and promote sustainable practices, aiming for long-term positive impacts on people and the planet.
Kenvue (NYSE: KVUE) announced its participation in Deutsche Bank's dbAccess Global Consumer Conference in Paris, France. Key executives, including CEO Thibaut Mongon, CFO Paul Ruh, and Group President Carlton Lawson, will engage in a fireside chat on June 4, 2024, at 8:45 a.m. Eastern Time / 2:45 p.m. Central European Time. The session will be webcast live on Kenvue's investor relations website, with a replay available afterward. Kenvue, a leading pure-play consumer health company with renowned brands such as Aveeno, BAND-AID, Johnson’s, Listerine, Neutrogena, and Tylenol, is committed to leveraging everyday care for consumer well-being.
Kenvue (NYSE: KVUE) announced the pricing of its secondary underwritten public offering of 182,329,550 shares of common stock at $20.00 per share, expected to close on May 17, 2024.
Kenvue will not sell any shares or receive proceeds from the offering. Instead, Johnson & Johnson (NYSE: JNJ) is expected to exchange these shares for its indebtedness held by Goldman Sachs & Co. and J.P. Morgan, who will then sell the shares to underwriters.
Post-offering, Johnson & Johnson will no longer own any shares of Kenvue. The offering will be managed by Goldman Sachs, J.P. Morgan, BofA Securities, and others. A registration statement on Form S-1 has been filed and declared effective by the SEC.
Kenvue Inc. (NYSE: KVUE) has announced the launch of a secondary underwritten public offering of 182,329,550 shares of its common stock. The offering involves the exchange of shares between Kenvue and Johnson & Johnson, with Goldman Sachs & Co. and J.P. Morgan acting as selling shareholders. Following the exchange, the selling shareholders will sell the shares to underwriters. Johnson & Johnson will no longer own any shares of Kenvue's common stock after the completion of the offering.
Kenvue Inc. (NYSE: KVUE) reported first quarter 2024 results with a 1.1% increase in net sales to $3.9 billion and 1.9% organic growth. Diluted earnings per share were $0.15, adjusted to $0.28. Gross profit margin expanded to 57.6%, operating income margin was 14.1%. Initiatives were approved to reduce the global workforce by 4% with cost savings of $350 million by 2026. Outlook for 2024 includes a reported net sales growth of 1.0% to 3.0% and adjusted diluted earnings per share in the range of $1.10 - $1.20.
Kenvue Inc. (NYSE: KVUE) has had its near-term greenhouse gas emissions reduction targets validated by the Science Based Targets initiative (SBTi), aligning with efforts to limit global temperature rise. The company commits to a 42% reduction in absolute Scope 1 and 2 GHG emissions by 2030 compared to 2020 levels. Additionally, Kenvue aims for 75% of its suppliers to have science-based targets by 2028. This validation underscores the company's dedication to combating climate change and advancing its Healthy Lives Mission, focusing on the well-being of people and the planet.
FAQ
What is the current stock price of Kenvue (KVUE)?
What is the market cap of Kenvue (KVUE)?
